NASDAQ:IMGN ImmunoGen (IMGN) Stock Forecast, Price & News $15.87 -0.13 (-0.81%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$15.76▼$16.1150-Day Range$14.09▼$19.5252-Week Range$3.61▼$20.69Volume3.64 million shsAverage Volume3.20 million shsMarket Capitalization$3.95 billionP/E RatioN/ADividend YieldN/APrice Target$22.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ImmunoGen MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44.1% Upside$22.88 Price TargetShort InterestBearish7.54% of Shares Sold ShortDividend StrengthN/ASustainability-0.49Upright™ Environmental ScoreNews Sentiment0.62Based on 8 Articles This WeekInsider TradingSelling Shares$25.38 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.12) to $0.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.60 out of 5 starsMedical Sector125th out of 972 stocksPharmaceutical Preparations Industry34th out of 446 stocks 4.5 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.88, ImmunoGen has a forecasted upside of 44.1% from its current price of $15.87.Amount of Analyst CoverageImmunoGen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.54% of the outstanding shares of ImmunoGen have been sold short.Short Interest Ratio / Days to CoverImmunoGen has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in ImmunoGen has recently decreased by 1.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 74.75% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.49. Previous Next 2.0 News and Social Media Coverage News SentimentImmunoGen has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for ImmunoGen this week, compared to 3 articles on an average week.Search InterestOnly 16 people have searched for IMGN on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,378,783.00 in company stock.Percentage Held by InsidersOnly 5.07% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow in the coming year, from ($0.12) to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -22.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -22.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 22.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ImmunoGen (NASDAQ:IMGN) StockImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.Read More IMGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMGN Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comImmunoGen, Inc. (NASDAQ:IMGN) Given Consensus Recommendation of "Buy" by AnalystsSeptember 28, 2023 | finance.yahoo.comELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian CancerOctober 1, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 25, 2023 | americanbankingnews.comZacks Research Comments on ImmunoGen, Inc.'s Q2 2024 Earnings (NASDAQ:IMGN)September 23, 2023 | americanbankingnews.comQ4 2024 EPS Estimates for ImmunoGen, Inc. (NASDAQ:IMGN) Lifted by Zacks ResearchSeptember 21, 2023 | americanbankingnews.comTheresa Wingrove Sells 192,013 Shares of ImmunoGen, Inc. (NASDAQ:IMGN) StockSeptember 21, 2023 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Stock Price Down 2.7% After Insider SellingSeptember 20, 2023 | benzinga.comOn the Road to Halving Cancer: The 2023 Biotech Advancements Igniting HopeOctober 1, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 18, 2023 | marketwatch.comImmunoGen Names Lauren White as Finance ChiefSeptember 18, 2023 | finance.yahoo.comImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial OfficerSeptember 18, 2023 | markets.businessinsider.comImmunoGen Appoints Lauren White As CFOSeptember 14, 2023 | 247wallst.comJP Morgan Upgrades ImmunogenSeptember 14, 2023 | nasdaq.comJP Morgan Upgrades Immunogen (IMGN)September 13, 2023 | msn.comImmunoGen gains as J.P. Morgan upgrades to overweight on favorable outlook for ElahereSeptember 13, 2023 | markets.businessinsider.comOvarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP MorganSeptember 7, 2023 | barrons.comImmunogen Inc.August 30, 2023 | msn.comImmunogen (IMGN) Price Target Increased by 6.47% to 24.25August 29, 2023 | markets.businessinsider.com10 Analysts Have This to Say About ImmunogenAugust 29, 2023 | msn.comImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?August 28, 2023 | benzinga.comImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In JapanAugust 28, 2023 | msn.comImmunoGen (NASDAQ:IMGN) Teams up with Takeda to Advance Elahere in JapanAugust 9, 2023 | seekingalpha.comImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade)August 2, 2023 | msn.comHC Wainwright & Co. Maintains Immunogen (IMGN) Buy RecommendationAugust 2, 2023 | seekingalpha.comImmunoGen medical chief steps downAugust 2, 2023 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on ImmunoGen (IMGN)August 2, 2023 | msn.comImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales BeatSee More Headlines Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address IMGN Company Calendar Last Earnings7/31/2023Today9/30/2023Next Earnings (Estimated)11/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Price Target and Rating Average Stock Price Forecast$22.88 High Stock Price Forecast$27.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+44.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-96.02% Pretax Margin-94.92% Return on Equity-76.92% Return on Assets-42.57% Debt Debt-to-Equity Ratio0.15 Current Ratio7.14 Quick Ratio7.11 Sales & Book Value Annual Sales$108.78 million Price / Sales36.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book22.35Miscellaneous Outstanding Shares248,940,000Free Float236,322,000Market Cap$3.95 billion OptionableOptionable Beta1.00 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Mark Joseph Enyedy (Age 59)Pres, CEO & Director Comp: $1.28MMs. Renee Lentini (Age 45)VP of Fin. & Chief Accounting Officer Comp: $430.52kMs. Stacy A. Coen (Age 52)Sr. VP & Chief Bus. Officer Comp: $584.04kDr. Michael J. Vasconcelles M.D. (Age 60)Ph.D., Chief Medical Officer Comp: $304.62kMs. Lauren A. White M.B.A. (Age 44)Sr. VP & Chief Financial Officer Anabel ChanHead of Investor RelationsMr. Daniel S. Char J.D. (Age 62)Sr. VP, Chief Legal Officer & Sec. Ms. Courtney O'KonekSr. Director of Corp. Communications & Investor RelationsMs. Audrey BerganSr. VP & Chief HR OfficerDr. Theresa G. Wingrove (Age 65)Sr. VP of Regulatory Affairs & Quality More ExecutivesKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSDynavax TechnologiesNASDAQ:DVAXIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsBarclays PLCSold 584,193 shares on 9/21/2023Ownership: 0.107%Theresa WingroveSold 192,013 sharesTotal: $2.96 M ($15.44/share)Virginia Retirement Systems ET ALBought 13,500 shares on 8/22/2023Ownership: 0.005%California State Teachers Retirement SystemBought 18,824 shares on 8/21/2023Ownership: 0.110%Teachers Retirement System of The State of KentuckySold 135,075 shares on 8/21/2023Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions IMGN Stock - Frequently Asked Questions Should I buy or sell ImmunoGen stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMGN shares. View IMGN analyst ratings or view top-rated stocks. What is ImmunoGen's stock price forecast for 2023? 7 analysts have issued 1 year target prices for ImmunoGen's shares. Their IMGN share price forecasts range from $16.00 to $27.00. On average, they anticipate the company's stock price to reach $22.88 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts. How have IMGN shares performed in 2023? ImmunoGen's stock was trading at $4.96 at the beginning of the year. Since then, IMGN stock has increased by 220.0% and is now trading at $15.87. View the best growth stocks for 2023 here. When is ImmunoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023. View our IMGN earnings forecast. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) released its earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The biotechnology company earned $83.20 million during the quarter, compared to analyst estimates of $49.15 million. ImmunoGen had a negative net margin of 96.02% and a negative trailing twelve-month return on equity of 76.92%. The firm's revenue for the quarter was up 485.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) earnings per share. What ETFs hold ImmunoGen's stock? ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR), iShares Micro-Cap ETF (IWC), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco DWA SmallCap Momentum ETF (DWAS) and iShares Biotechnology ETF (IBB). What guidance has ImmunoGen issued on next quarter's earnings? ImmunoGen updated its FY 2023 earnings guidance on Monday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million. What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX). What is ImmunoGen's stock symbol? ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN." How do I buy shares of ImmunoGen? Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ImmunoGen's stock price today? One share of IMGN stock can currently be purchased for approximately $15.87. How much money does ImmunoGen make? ImmunoGen (NASDAQ:IMGN) has a market capitalization of $3.95 billion and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. How many employees does ImmunoGen have? The company employs 277 workers across the globe. Does ImmunoGen have any subsidiaries? The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..Read More How can I contact ImmunoGen? ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611. This page (NASDAQ:IMGN) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.